Inhibition of autophagy in peripheral blood mononuclear cells by vaginal fluid from women with a malignant adnexal mass

Inhibition of autophagy is a characteristic of ovarian cancer. We determined whether inhibition of autophagy by vaginal fluid could provide a non‐invasive test for cancer risk stratification in women presenting with an adnexal mass. Vaginal fluid supernatants from 90 women undergoing evaluation for a suspicious adnexal mass were incubated with peripheral blood mononuclear cells (PBMCs) obtained from healthy women under conditions that induce autophagy. Rapamycin, an autophagy inducer, was added to some cultures. After 48 hr the cells were collected, lysed and assayed by ELISA for intracellular p62 concentration. p62 is a cytoplasmic protein that is consumed during autophagy induction. Its concentration is inversely proportional to the extent of autophagy induction. Clinical information including pathological diagnoses was obtained after completion of laboratory studies. Mean p62 levels were 9.4 ng/ml in the 21 women with a subsequent malignant diagnosis, 4.5 ng/ml in the eight women with a borderline tumor diagnosis and 3.6 ng/ml in the 61 women with benign disease (p < 0.0001, malignant vs. others). When rapamycin was added to the vaginal fluid‐PBMC co‐incubation, p62 levels in samples from women with a malignant diagnosis decreased to 3.3 ng/ml, a level comparable to what was observed with the nonmalignant samples. Vaginal fluid inhibition of autophagy can differentiate between women with malignant and benign adnexal masses.

[1]  E. Diamandis,et al.  Effectiveness of the Risk of Malignancy Index and the Risk of Ovarian Malignancy Algorithm in a Cohort of Women With Ovarian Cancer: Does Histotype and Stage Matter? , 2015, International Journal of Gynecologic Cancer.

[2]  K. Holcomb,et al.  Involvement of autophagy in cervical, endometrial and ovarian cancer , 2014, International journal of cancer.

[3]  Sang Gyun Kim,et al.  Rapamycin: one drug, many effects. , 2014, Cell metabolism.

[4]  S. Witkin,et al.  Inhibition of Autophagy by Sera From Pregnant Women , 2013, Reproductive Sciences.

[5]  H. Stenmark,et al.  p62 at the interface of autophagy, oxidative stress signaling, and cancer. , 2012, Antioxidants & redox signaling.

[6]  O. Camara,et al.  Preoperative Multimodal Strategies for Risk Assessment of Adnexal Masses: Analysis of 1362 Cases in a Gynecologic Cancer Center , 2011, International Journal of Gynecologic Cancer.

[7]  M. Komatsu,et al.  Selective degradation of p62 by autophagy , 2010, Seminars in Immunopathology.

[8]  Steven J Skates,et al.  Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. , 2010, American journal of obstetrics and gynecology.

[9]  B. Davidson,et al.  Mammalian target of rapamycin is a biomarker of poor survival in metastatic serous ovarian carcinoma. , 2010, Human pathology.

[10]  Mihee M. Kim,et al.  The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1 , 2010, Nature Cell Biology.

[11]  Zhen Lu,et al.  The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. , 2008, The Journal of clinical investigation.

[12]  R. Deng,et al.  Decreased expression of autophagy-related proteins in malignant epithelial ovarian cancer , 2008, Autophagy.

[13]  F. Bredin,et al.  Use of sirolimus (rapamycin) to treat refractory Crohn’s disease , 2008, Gut.

[14]  J. Flores,et al.  The signaling adaptor p62 is an important NF-kappaB mediator in tumorigenesis. , 2008, Cancer cell.

[15]  D. Klionsky,et al.  Autophagosome formation: core machinery and adaptations , 2007, Nature Cell Biology.

[16]  G. Bjørkøy,et al.  p62/SQSTM1 Binds Directly to Atg8/LC3 to Facilitate Degradation of Ubiquitinated Protein Aggregates by Autophagy* , 2007, Journal of Biological Chemistry.

[17]  T. Hagemann,et al.  The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. , 2007, Cancer research.

[18]  B. Rosen,et al.  Who should operate on patients with ovarian cancer? An evidence-based review. , 2005, Gynecologic oncology.

[19]  S. Emr,et al.  Autophagy as a regulated pathway of cellular degradation. , 2000, Science.

[20]  E J Pavlik,et al.  A morphology index based on sonographic findings in ovarian cancer. , 1993, Gynecologic oncology.

[21]  D. Oram,et al.  A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer , 1991, British journal of obstetrics and gynaecology.

[22]  R. Bast,et al.  A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. , 1983, The New England journal of medicine.

[23]  S. Ryter,et al.  Autophagy in human health and disease. , 2013, The New England journal of medicine.

[24]  Richard G. Moore,et al.  A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. , 2009, Gynecologic oncology.

[25]  R. Bast,et al.  The CA 125 tumour-associated antigen: a review of the literature. , 1989, Human reproduction.